鼻咽癌未受累颈部减体积照射:开放标签、非劣效、多中心、随机III期试验更新结果
该随机III期试验更新报告显示,中位随访74个月时,N0-1鼻咽癌患者采用选择性上颈照射与全颈照射的5年总生存率和区域无复发生存率相似,且上颈照射组甲状腺功能减退、颈部组织损伤、吞咽困难及下颈颈总动脉狭窄的发生率更低,放疗后循环淋巴细胞计数更高。
要点
- 中位随访74个月,上颈照射组与全颈照射组5年总生存率分别为95.9%与93.1%,HR 0.63(95%CI 0.30-1.35),P=0.24。
- 两组5年区域无复发生存率分别为95.0%与94.9%,HR 0.96(95%CI 0.43-2.13),P=0.91。
- 上颈照射组5年无病生存者甲状腺功能减退(34% vs 48%,P=0.004)、颈部组织损伤(29% vs 46%,P<0.001)、吞咽困难(14% vs 27%,P=0.002)及下颈颈总动脉狭窄(15% vs 26%,P=0.043)发生率均低于全颈照射组。
核心结论
- 更新数据证实,对N0-1鼻咽癌未受累颈部行选择性上颈照射是标准治疗,疗效优异且长期毒性降低,并可能保留更多免疫功能。
研究设计与样本
- 开放标签、非劣效、多中心、随机III期试验,患者随机接受选择性上颈照射(n=224)或全颈照射(n=222)治疗未受累颈部。
主要发现
- 中位随访74个月,上颈照射组与全颈照射组5年总生存率分别为95.9%与93.1%,HR 0.63(95%CI 0.30-1.35),P=0.24。
- 两组5年区域无复发生存率分别为95.0%与94.9%,HR 0.96(95%CI 0.43-2.13),P=0.91。
- 上颈照射组5年无病生存者甲状腺功能减退发生率为34%,全颈照射组为48%(P=0.004)。
- 上颈照射组5年无病生存者颈部组织损伤发生率为29%,全颈照射组为46%(P<0.001)。
- 上颈照射组5年无病生存者吞咽困难发生率为14%,全颈照射组为27%(P=0.002)。
临床怎么用
- 作者结论认为,对N0-1鼻咽癌未受累颈部行选择性上颈照射是标准治疗,疗效优异且长期毒性降低,并可能保留更多免疫功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We previously reported comparable 3-year regional relapse-free survival (RRFS) using elective upper-neck irradiation (UNI) in N0-1 nasopharyngeal carcinoma (NPC) compared with standard whole-neck irradiation (WNI). Here, we present the prespecified 5-year overall survival (OS), RRFS, late toxicity, and additional analyses. In this randomized trial, patients received UNI (n = 224) or WNI (n = 222) for an uninvolved neck. After a median follow-up of 74 months, the UNI and WNI groups had similar 5-year OS (95.9% v 93.1%, hazard ratio [HR], 0.63 [95% CI, 0.30 to 1.35]; P = .24) and RRFS (95.0% v 94.9%, HR, 0.96 [95% CI, 0.43 to 2.13]; P = .91) rates. The 5-year disease-free survivors in the UNI group had a lower frequency of hypothyroidism (34% v 48%; P = .004), neck tissue damage (29% v 46%; P < .001), dysphagia (14% v 27%; P = .002), and lower-neck common carotid artery stenosis (15% v 26%; P = .043). The UNI group had higher postradiotherapy circulating lymphocyte counts than the WNI group (median: 400 cells/μL v 335 cells/μL, P = .007). In conclusion, these updated data confirmed that UNI of the uninvolved neck is a standard of care in N0-1 NPC, providing outstanding efficacy and reduced long-term toxicity, and might retain more immune function.
引用
- Huang CL, Zhang N, Jiang W, et al. Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial. J Clin Oncol. 2024. PMID: 38507662. doi:10.1200/JCO.23.02086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。